Back to top
more

Achillion Pharmaceuticals, Inc. (ACHN)

(Delayed Data from NSDQ)

$2.96 USD

2.96
1,311,012

-0.05 (-1.66%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Achillion's Renal Disease Candidate Gets Orphan Drug Status

by Zacks Equity Research

Achillion Pharmaceuticals' (ACHN) factor D inhibitor, ACH-4471, gets orphan drug designation for treating C3G, a renal disease.

    Allergan Inks Deal to Buy Texas-Based Repros Therapeutics

    by Zacks Equity Research

    Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.

      Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma

      by Zacks Equity Research

      Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.

        Revance's Neuromodulator Injection Positive in Phase III

        by Zacks Equity Research

        Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.

          AstraZeneca's COPD Drug Succeeds in Label Expansion Study

          by Zacks Equity Research

          AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

            Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug

            by Zacks Equity Research

            Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.

              Celldex Begins Phase I Trial on Cancer Candidate CDX-1140

              by Zacks Equity Research

              Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.

                Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%

                by Zacks Equity Research

                Merck (MRK) rewards shareholders with a hike in quarterly dividend. Also, the company's board of directors sanctions a new stock buyback plan.

                  AstraZeneca Files for Label Expansion of Tagrisso in Japan

                  by Zacks Equity Research

                  AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

                    Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler

                    by Zacks Equity Research

                    Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.

                      Puma Inks License Deal to Commercialize Cancer Drug Nerlynx

                      by Zacks Equity Research

                      Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.

                        Agios Posts New Data on Glioma Candidate from Dose Expansion

                        by Zacks Equity Research

                        Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.

                          Achillion (ACHN) Shares Down as J&J Announces Stake Sale

                          by Zacks Equity Research

                          Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer

                            by Arpita Dutt

                            Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.

                              Cardinal Health (CAH) to Divest Assets to Shanghai Pharma

                              by Zacks Equity Research

                              Cardinal Health (CAH) will streamline its Chinese operations by disposing pharmaceutical and medical products distribution business in China.

                                Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

                                by Zacks Equity Research

                                Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.

                                  Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

                                  by Zacks Equity Research

                                  GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.

                                    Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus

                                    by Zacks Equity Research

                                    Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.

                                      Achillion's HCV Partnership with J&J Terminated, Stock Falls

                                      by Zacks Equity Research

                                      Achillion Pharmaceuticals (ACHN) suffered a setback as Janssen terminated their worldwide license and collaboration arrangement on hepatitis C.

                                        Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update

                                        by Zacks Equity Research

                                        Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.

                                          Is the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock?

                                          by Zacks Equity Research

                                          Investors need to pay close attention to Achillion Pharmaceuticals (ACHN) stock based on the movements in the options market lately.

                                            Achillion (ACHN) Up 31.1% Since Earnings Report: Can It Continue?

                                            by Zacks Equity Research

                                            Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              Achillion (ACHN) Reports Wider-than-Expected Loss in Q1

                                              by Zacks Equity Research

                                              Achillion Pharmaceuticals, Inc. (ACHN) reported a loss of 15 cents per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of 8 cents. In the year-ago quarter, the company had reported a loss of 13 cents per share.

                                                Why Is Achillion (ACHN) Down 11.3% Since the Last Earnings Report?

                                                by Zacks Equity Research

                                                Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?

                                                  by Zacks Equity Research

                                                  Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.